IM8N Stock Chart & Stats
CHF95.97
CHF0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeCHF90.42 - CHF95.97
Previous CloseN/A
VolumeN/A
Average Volume (3M)11.00
Market Cap
CHF20.12B
Enterprise ValueCHF22.76B
Total Cash (Recent Filing)CHF1.16B
Total Debt (Recent Filing)CHF579.88M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Oct 22, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.11
Shares Outstanding218,381,500
10 Day Avg. Volume11
30 Day Avg. Volume11
Financial Highlights & Ratios
PEG Ratio-1.80
Price to Book (P/B)50.31
Price to Sales (P/S)61.31
P/FCF Ratio-38.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF164.59Price Target Upside― Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)-1.32
Revenue Forecast (FY)CHF1.49B
Bulls Say, Bears Say
Bulls Say
BRINSUPRI Commercial Launch MomentumRapid BRINSUPRI adoption, expanding prescriber depth, and higher guidance indicate strong commercial execution and broadening patient uptake. Sustained starts across future quarters could establish a durable revenue base, improve operating leverage, and materially diversify Insmed beyond ARIKAYCE.
TPIP Clinical And Pipeline AdvancementDurable improvements in walking distance, biomarkers, functional class, and risk scores support TPIP’s potential differentiation in a high-need rare disease market. Progress into Phase 3, alongside additional pipeline programs, strengthens Insmed’s longer-term growth platform.
Strong Revenue Growth And Gross MarginAccelerating revenue growth combined with a high and improving gross margin shows that Insmed’s commercial products can generate substantial gross profit as scale increases. This provides a foundation for funding launches and pipeline development, even before operating profitability is achieved.
Bears Say
Heavy Cash Burn And Negative Free Cash FlowThe scale of operating and free-cash-flow losses remains a major constraint on financial durability. Continued investment in launches and clinical programs consumes substantial liquidity, leaving Insmed dependent on successful commercialization and its projected 2027 cash-flow inflection.
Operating Profitability Remains Deeply NegativeDespite strong gross margins, Insmed has not yet demonstrated operating breakeven, and very negative net margins show that expenses materially exceed product economics. Persistent losses can limit financial flexibility and make execution on multiple launches and trials more important.
International And Forecast Execution RisksEuropean reimbursement constraints may reduce international revenue upside relative to earlier expectations, while major pipeline forecasts depend on several favorable clinical, regulatory, diagnosis, pricing, and competitive outcomes. These factors make the longer-term growth outlook execution-sensitive.
Insmed News
IM8N FAQ
What was Insmed’s price range in the past 12 months?
Insmed lowest stock price was CHF90.42 and its highest was CHF95.97 in the past 12 months.
What is Insmed’s market cap?
Insmed’s market cap is CHF20.12B.
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is Oct 22, 2026 which is in 17 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on Aug 06, 2026. The company reported -CHF0.05 earnings per share for the quarter, beating the consensus estimate of -CHF0.557 by CHF0.508.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Undervalued.
Does Insmed pay dividends?
Insmed does not currently pay dividends.
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -0.32.
How many shares outstanding does Insmed have?
Insmed has 218,381,500 shares outstanding.
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -CHF0.05 in its last earnings report, beating expectations of -CHF0.557. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Insmed?
Currently, no hedge funds are holding shares in CH:IM8N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insmed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF164.59 (― Upside)
CHF164.59 (― Upside)
Blogger Sentiment
Bullish
CH:IM8N Sentiment 73%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth CHF29.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Insmed
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
IM8N Company Deck
IM8N Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong commercial execution and materially improved financial and clinical momentum — highlighted by BRINSUPRI’s historic launch ($309.2M Q2, raised FY guidance to $1.25B–$1.4B, peak >$7B), solid ARIKAYCE performance ($116.3M, +8% YoY) and compelling TPIP clinical data with upgraded peak potential (> $6B). Management emphasized a healthy cash position (~$1.2B) and a clear path to cash-flow positivity in 2027. Offsetting risks include higher near-term operating spend (R&D and SG&A +38% YoY), European reimbursement headwinds, milestone payments (~$50M H2 2026), and reliance on optimistic assumptions (diagnosis expansion, regulatory success, pricing). Overall, the positive commercial results, clinical readouts and funding runway substantially outweigh the noted operational and market uncertainties.View all CH:IM8N earnings summariesIM8N Stock 12 Month Forecast
Average Price Target
―Alnylam Pharma
―
BioMarin Pharmaceutical
―
United Therapeutics
―
Ultragenyx Pharmaceutical
―
Avalyn Pharma Inc
―